Details of the Drug Reposition

General Information of This Drug (ID: DMHJTR2)

Drug Name
XL880   DMHJTR2
Synonyms GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
4 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastric adenocarcinoma DISWWLTC 2B72 Phase 2 [1]
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [2]
Renal cell carcinoma DISQZ2X8 2C90 Phase 2 [1]
Squamous head and neck cell carcinom DIS0UVDG 2D60.0 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [1]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5679).
2 ClinicalTrials.gov (NCT01147484) A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer (IND197). U.S. National Institutes of Health.